Dyskinesia- Pipeline Insight, 2024

Dyskinesia- Pipeline Insight, 2024

DelveInsight’s, “Dyskinesia- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Dyskinesia: Understanding

Dyskinesia: Overview

Dyskinesia’s are involuntary, erratic, writhing movements of the face, arms, legs or trunk. They are often fluid and dance-like, but they may also cause rapid jerking or slow and extended muscle spasms. They are not a symptom of Parkinson's itself. Rather, they are a complication from some Parkinson's medications. They may be caused by systemic, metabolic, endocrinologic, structural, vascular, infectious or inherited degenerative conditions, or be toxin- or drug-induced. Dyskinesia’s usually begin after a few years of treatment with levodopa and can often be alleviated by adjusting dopaminergic medications. Younger people with PD are thought to develop earlier motor fluctuations and dyskinesia’s in response to levodopa.

Dyskinesias may be mild and non-bothersome, or they can be severe. Most people with Parkinson’s prefer to be “on” with some dyskinesias rather than “off” and unable to move well. However, for some people, dyskinesias can be severe enough that they interfere with normal functioning. Dyskinesia is a complication of long-term levodopa use in people who have had Parkinson's for several years. Other risk factors include being younger at diagnosis and using higher amounts of levodopa for longer periods of time. Involuntary movement is the chief symptom of dyskinesia. This can present in only one part of the body, such as a person’s arm or leg, or it can affect the whole body. Common symptoms include writhing or wriggling, head bobbing, fidgeting, rocking, swaying some other symptoms also relates to rapid blinking, waving of the arms or hands, sticking out the tongue, a random movement of the lips, tongue, or jaw, some movements in the limbs, fingers, and toes, swaying movements of the hips or torso in severe cases, difficulty breathing, also in severe cases.

The treatment options used to treat the disease includes changing the dose and/or timing of levodopa so get enough in each dose to control the symptoms but not too much that it causes dyskinesia. Switching to a different formulation of levodopa, such as extended-release (Rytary) or the gel infusion (Duopa). These drugs aim to keep dopamine levels steady to control symptoms and limit dyskinesia.

Adding amantadine. Gocovri (amantadine extended release) works on the glutamate brain chemical system to lessen dyskinesia. Prior to Gocovri's 2017 FDA approval, amantadine immediate-release often was (and still may be) used in some cases. Undergoing deep brain stimulation (DBS), a surgical procedure. This is not an option for everyone. But DBS may be considered for those who've had Parkinson's for at least four years, benefit from levodopa, and have dyskinesia or significant ""off"" time — periods when medication isn't working well and symptoms return.

""Dyskinesia- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dyskinesia pipeline landscape is provided which includes the disease overview and Dyskinesia treatment guidelines. The assessment part of the report embraces, in depth Dyskinesia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dyskinesia R&D. The therapies under development are focused on novel approaches to treat/improve Dyskinesia.

Dyskinesia Emerging Drugs Chapters

This segment of the Dyskinesia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dyskinesia Emerging Drugs

P-1037 IS : Parion Sciences

P-1037 IS is, a novel, small molecule long acting ENaC Inhibitor delivered in a nebulized solution, was well tolerated at the doses tested in multiple clinical trials in healthy volunteers and patients with muco-obstructive lung disease, including primary ciliary dyskinesia (PCD). Inhibiting the ENaC activity in PCD patients with P-1037 IS has been shown to improve airway mucus hydration and allow for more efficient mucus clearance in patients with PCD, thus leading to improved lung function. The drug candidate has also received Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation from FDA. Currently, the drug is in Phase II stage of its development for the treatment of dyskinesia.

NLX 112 : Neurolixis

NLX-112 (also known as befiradol or F13640) is a novel small molecule compound that activates serotonin 5-HT1A receptors. NLX-112 is extremely selective for the 5-HT1A receptor, with over 1000-fold selectivity compared to other types of receptor types, and NLX-112 is a full agonist at 5-HT1A receptors, maximally activating the receptor. It strongly reduces L-DOPA-induced abnormal movements ('dyskinesias') in animal models of Parkinson's disease (PD). Currently, the drug is in Phase II stage of its development for the treatment of dyskinesia.

DSP-9632P : Sumitomo Dainippon Pharma

DSP-9632P is a serotonin 5-HT1A receptor partial agonist. It is expected to exert an effect on dyskinesia expressed after administration of levodopa by suppressing the excessive release of levodopa-derived dopamine. Pre-clinical studies suggest DSP-9632P suppresses the dyskinesia symptom induced by levodopa. The transdermal patch formulation of DSP-9632P could potentially have an effective treatment option for levodopa-induced dyskinesia in Parkinson's disease by showing stable blood concentration, and may also lead to improved convenience for patients in terms of drug administration. Currently, the drug is in Phase I stage of its development for the treatment of dyskinesia.

JM-010 : Contera Pharma

IVW-1001 is a novel small molecule that acts as a dual molecular switch by which the target efficacies of two existing and safe medications are perfectly fine-tuned to effectively treat the disease. Using a proprietary formulation, JM-010 targets central mechanisms underlying the development of dyskinesia in Parkinson’s disease. JM-010 has successfully demonstrated its efficacy and safety in preclinical studies, as well as in Ph1 clinical safety and Ph2 clinical proof of concept studies. Currently, the drug is in Phase II stage of its development for the treatment of dyskinesia.

Further product details are provided in the report……..

Dyskinesia: Therapeutic Assessment

This segment of the report provides insights about the different Dyskinesia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dyskinesia

There are approx. 20+ key companies which are developing the therapies for Dyskinesia. The companies which have their Dyskinesia drug candidates in the most advanced stage, i.e. phase III include, Parion Sciences

Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dyskinesia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dyskinesia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dyskinesia drugs.

Dyskinesia Report Insights

Dyskinesia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Dyskinesia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Dyskinesia drugs?

How many Dyskinesia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dyskinesia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dyskinesia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Dyskinesia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Parion Sciences

Neurolixis

Sumitomo Dainippon Pharma

Contera Pharma

ReCode Therapeutics

Integrative Research Laboratories

Luye Pharma Group

Celon Pharma

VistaGen Therapeutics, Inc.

Novartis

MapLight Therapeutics

Ethris

Contera Pharma

Teva Pharmaceutical

Sinopia Biosciences

SOM Biotech

Cycle Pharmaceuticals

Medicure Inc.

Key Products

P-1037 IS

NLX 112

DSP-9632P

JM-010

RCT1100

Mesdopetam (IRL790)

LPM3770164

CPL500036

AV-101

AQW051

ML-007C-MA

ETH 42

ETH 43

ETH 44

CP 011

Deutetrabenazine

SB-0107

SOM 3366

Research Programme: Cycle Pharmaceuticals

TARDOXAL